Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study

Zhichao Tian1 · Jiaqiang Wang1 · Jinpo Yang2 · Peng Zhang1 · Xin Wang1 · Fan Zhang1 · Po Li1 · Weitao Yao1

Received: 17 March 2021 / Accepted: 14 June 2021 / Published online: 22 June 2021
© The Author(s) 2021

Summary

Background  There is a need to establish an effective neoadjuvant therapy for soft tissue sarcomas (STSs). We previously showed that apatinib, administered in combination with doxorubicin-based chemotherapy, improves the efficacy of treatment. This study aimed to clarify the effectiveness and safety of apatinib combined with doxorubicin and ifosfamide (AI) neoadjuvant chemotherapy for STSs.

Methods  This retrospective study included patients with STS who received neoadjuvant therapy and surgery between January 2016 and January 2019. The patients were divided into two treatment groups: AI + apatinib group and AI group (doxorubicin + ifosfamide).

Results  The study included 74 patients (AI + apatinib: 26, AI: 48) with STS. There were significant between-group differences in objective response rates (53.85% vs. 29.17%, p = 0.047) and the average change in target lesion size from baseline (-40.46 ± 40.30 vs. -16.31 ± 34.32, p = 0.008). The R0 rate (84.62% vs. 68.75%; p = 0.170) and 2-year disease-free survival (73.08% vs. 62.50%, p = 0.343) were similar across groups. Finally, the rates of neoadjuvant therapy-related adverse effects and postoperative complications were similar in both groups (p > 0.05).

Conclusion  Apatinib plus doxorubicin and ifosfamide regimen is safe and effective as neoadjuvant therapy for patients with STS. However, the significantly improved preoperative ORR observed after neoadjuvant therapy did not translate into a significantly improved R0 rate and 2-year DFS. Prospective, well-powered studies are warranted to determine the long-term efficacy and optimal application of these protocols.

Keywords  Apatinib · Doxorubicin · Ifosfamide · Sarcoma · Neoadjuvant therapy

Background

There are over 70 subtypes of soft tissue sarcomas (STSs) [1]. Although rare, STS accounts for approximately 40,000 new diagnoses in China each year [2]. The standard treatment for localized STS is surgical resection [3]. Despite achieving optimal local control, over 50% of patients with localized STS succumb to metastatic disease [4]. The first-line treatment for advanced (locally unresectable or metastatic) STS is chemotherapy with doxorubicin [3]. The overall response rate (ORR) to this treatment for advanced STS is approximately 20% [5], and the 5-year survival rate among patients with advanced STS treated with a combination regimen is <10% [6]. These findings suggest the need for an approach that may help reduce the rates of recurrence and metastasis in patients with early- and mid-stage STS. Neoadjuvant chemotherapy (preoperative adjuvant chemotherapy) is a candidate approach in this context [7].

Despite this need, the efficacy of neoadjuvant chemotherapy for STS remains controversial as evidence from clinical trials has failed to convincingly demonstrate the effectiveness of neoadjuvant chemotherapy for STS [8–10]. Due to the ongoing debate over the efficacy of neoadjuvant chemotherapy, the STS research community worldwide is examining ways to improve the efficacy of neoadjuvant therapy [10–13]. This improvement can be achieved by using more sensitive treatment methods or implementing
individualized therapy based on sarcoma subtypes. Determining an effective neoadjuvant therapy remains an ongoing research priority.

Apatinib is a multi-target tyrosine kinase inhibitor (TKI), marketed in China, that effectively treats some types of STS [14, 15]. As a leading sarcoma treatment center in central China, we have treated many patients with STS with apatinib [14, 16]. In fact, we previously showed that apatinib combined with doxorubicin was more effective than doxorubicin alone in reducing the size of target lesions in patients with STS [17]. This finding suggests that the use of apatinib combined with doxorubicin-based chemotherapy may improve the efficacy of neoadjuvant therapy. Based on this evidence, we treated some STS patients with apatinib combined with doxorubicin and ifosfamide (AI) neoadjuvant chemotherapy over the past few years. In this study, we retrospectively examined these patients’ clinical data to clarify the effectiveness and safety of apatinib combined with neoadjuvant chemotherapy for treating STS. The present findings may provide a reference for clinical treatment decision-making and future clinical trial design.

Material and methods

Patients and eligibility criteria

This retrospective study included patients with STS treated at the Affiliated Cancer Hospital of Zhengzhou University between January 2016 and January 2019. Patients were included in the present study if they: 1) had pathologically confirmed STS, 2) were identified as high-risk patients without evidence of distant metastasis [18], 3) received two cycles of AI or AI+apatinib neoadjuvant therapy, 4) underwent resection of the primary lesion, and 5) had complete follow-up data.

This study was approved by the Ethics Committee of the Affiliated Cancer Hospital of Zhengzhou University. Included patients provided written informed consent for their participation. The study complied with the Declaration of Helsinki guidelines and any other relevant reporting or ethical guidelines.

Treatment protocol

Patients were divided into AI+apatinib and AI groups based on the type of neoadjuvant therapy they received. In the AI+apatinib group, patients were administered 37.5 mg/m² doxorubicin per day in the form of a short infusion on days 1 and 2; and 2 g/m² of ifosfamide per day in the form of an intravenous bolus on days 1–3. The treatment procedure was repeated on day 21. Simultaneously, patients in parallel received 500 mg apatinib once daily, starting on day 1. Apatinib was discontinued on day 35.

In the AI group, patients were administered 37.5 mg/m² of doxorubicin per day in the form of a short infusion on days 1 and 2; and 2 g/m² ifosfamide per day of an intravenous bolus on days 1–3. The treatment procedure was repeated on day 21.

Patients were assessed for signs of toxicity, according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. In cases of severe toxicity, treatment with apatinib and doxorubicin was delayed until patient recovery, for a maximum of 14 days.

Surgical resection

Extensive resection of the primary lesion was performed on days 35–45. Patients were confirmed to be free of grade 3–4 adverse events (AEs) at the time of surgery. All surgeries were performed by an experienced STS surgical team. Each surgery aimed to achieve macroscopically complete resection of the tumor mass based on preoperative assessment and intraoperative findings. All operations were routine and non-minimally invasive. No patients received further apatinib or chemotherapy after surgery. All patients received adjuvant radiotherapy after surgery.

Evaluation

The effectiveness of neoadjuvant therapy was evaluated preoperatively with enhanced magnetic resonance imaging and computed tomography scans, according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Between-group differences in the ORR, target lesion diameter changes from baseline, R0 rate, and 2-year disease-free survival (DFS) were assessed. DFS was defined as the time from surgical resection to signs of recurrence or metastasis or disease-related death, whichever occurred first. The rates of neoadjuvant therapy-related and surgical resection-related AEs were compared between the groups. Surgical resection-related AEs were graded by the Clavien-Dindo grading system.

Statistical analysis

All statistical analyses were performed using SPSS 21.0 software for Windows. Data are presented as medians (range) or counts (percentage). The Wilcoxon rank-sum test with continuity correction was used to analyze continuous variables. Fisher’s exact test was used for the analysis of categorical variables. All statistical analyses were two-sided, and p-values < 0.05 were considered indicative of a statistically significant difference. This was a descriptive analysis.
Results

Patients’ characteristics

A total of 74 patients with STS met the eligibility criteria for this study and subsequently assigned to the AI + apatinib (n = 26) and AI (n = 48) groups. The patients’ baseline characteristics were similar between groups and are presented in Table 1. Both groups featured more females than males. The median ages of patients in the AI + apatinib and AI groups were 42.04 ± 14.84 and 44.52 ± 13.34 years. The group members’ Eastern Cooperative Oncology Group Performance Status scores ranged from 0–1. The primary lesions were most commonly located in the extremities, followed by the trunk and the head and neck. The distribution of histological subtypes in the AI + apatinib group was as follows: undifferentiated sarcoma (n = 7), synovial sarcoma (n = 6), leiomyosarcoma (n = 4), angiosarcoma (n = 4), fibrosarcoma (n = 3), rhabdomyosarcoma (n = 3), and malignant peripheral nerve sheath tumor (MPNST) (n = 1). The distribution of histological subtypes in the AI group was as follows: undifferentiated sarcoma (n = 9), synovial sarcoma (n = 12), leiomyosarcoma (n = 11), angiosarcoma (n = 3), fibrosarcoma (n = 4), rhabdomyosarcoma (n = 5), MPNST (n = 2), and liposarcoma (n = 2). The mean diameters of primary lesions in the AI + apatinib and AI groups were 10.13 ± 5.21 and 9.89 ± 4.36 cm, respectively. Baseline characteristics were similar between the groups (Table 1).

Effectiveness of the treatment

Neoadjuvant therapy effectiveness was evaluated preoperatively, after administration of neoadjuvant therapy. In the AI + apatinib group, one patient with undifferentiated sarcoma and another with synovial sarcoma achieved complete response (CR) (Fig. 1). In contrast, no patient in the AI group achieved CR. There were significant between-group differences in ORR (53.85% vs. 29.17%, p = 0.047; Table 2) and the average change in target lesion size from baseline (- 40.46 ± 40.30 vs. -16.31 ± 34.32, p = 0.008; Table 2 and Fig. 1).

Postoperative effectiveness evaluation included R0 excision rate and 2-year DFS. There was no significant difference in R0 rate (84.62% vs. 68.75%; p = 0.170; Table 3) or the 2-year DFS (73.08% vs. 62.50%, p = 0.343; Table 2 and Fig. 2).

Ancillary analysis

To investigate the effect of sarcoma histological subtypes on neoadjuvant therapy outcomes, we evaluated treatment outcomes after excluding patients with undifferentiated sarcoma. As shown in Table 3 and Fig. 2, we found a significant between-group difference in 2-year DFS (84.20% vs. 61.51%, P = 0.047).

Toxicity evaluation

The major neoadjuvant therapy-related AEs observed in the groups are presented in Table 4. Neoadjuvant therapy-related AEs were more common in the AI + apatinib group than in the AI group; however, this difference did not rise to the level of statistical significance (p > 0.05, Table 4). Most patients experienced grade 1 or 2 AEs, and a few patients experienced grade 3 or 4 AEs. No drug-related deaths occurred.

Postoperative complications per treatment group are presented in Table 5. Grade IV (Clavien-Dindo grading) complications—including cardiac failure and deep venous thrombosis—occurred once in the AI + apatinib and AI groups, respectively. No perioperative deaths occurred. There was no statistically significant between-group difference in the incidence of postoperative complications (P > 0.05, Table 5).

Table 1 Patient characteristics by treatment group

| Characteristics          | AI + apatinib group (n = 26) | AI group (n = 48) | P—value |
|--------------------------|-------------------------------|-------------------|---------|
| Sex                      |                               |                   | 0.807   |
| Male                     | 11 (42.31%)                   | 23 (47.92%)       |         |
| Female                   | 15 (57.69%)                   | 25 (52.08%)       |         |
| Median age (years)       | 42.04 ± 14.84                 | 44.52 ± 13.34     | 0.465   |
| ECOG PS                  |                               |                   | 1.000   |
| 0                        | 21 (80.77%)                   | 37 (77.08%)       |         |
| 1                        | 5 (19.23%)                    | 11 (22.92%)       |         |
| 2                        | 0                             | 0                 |         |
| Primary tumor site       |                               |                   | 0.835   |
| Extremities              | 16 (61.54%)                   | 26 (54.17%)       |         |
| Trunk                    | 7 (30.77%)                    | 15 (31.25%)       |         |
| Head and neck            | 3 (11.54%)                    | 7 (14.58%)        |         |
| Histological types       |                               |                   | 0.768   |
| Undifferentiated sarcoma | 7 (30.77%)                    | 9 (18.75%)        |         |
| Synovial sarcoma         | 6 (23.08%)                    | 12 (25.00%)       |         |
| Leiomyosarcoma           | 4 (15.38%)                    | 11 (22.92%)       |         |
| Angiosarcoma             | 4 (15.38%)                    | 3 (6.25%)         |         |
| Fibrosarcoma             | 3 (11.54%)                    | 4 (8.33%)         |         |
| Rhabdomyosarcoma         | 1 (3.85%)                     | 5 (10.42%)        |         |
| MPNST                    | 1 (3.85%)                     | 2 (4.17%)         |         |
| Liposarcoma              | 0                             | 2 (4.17%)         |         |
| Mean tumor size (cm)     | 10.13 ± 5.21                  | 9.89 ± 4.36       | 0.910   |

Data are presented as counts (percentages) or means ± standard deviations

AI neoadjuvant chemotherapy with doxorubicin and ifosfamide, ECOG PS Eastern Cooperative Oncology Group performance status, MPNST malignant peripheral nerve sheath tumor
Discussion

Previous studies have demonstrated that combinations of multi-target TKIs and cytotoxic chemotherapy can overcome chemoresistance [15, 19]. Apatinib may act as an effective chemotherapy sensitizer for reducing doxorubicin-induced chemoresistance [20]. The present study findings support this conclusion. This study’s ORR was higher than the previous study [17]. This increase was likely due to the addition of ifosfamide to the chemotherapy regimen. The aim of neoadjuvant therapy is to reduce the diameter of the target lesion, thus simplifying surgery (Fig. 3). Nevertheless, neoadjuvant therapy may increase the risk of disease progression, rendering surgery impossible. This suggests
that an intensive neoadjuvant regimen may be required to concurrently minimize the risk of disease progression and reduce the target lesion size. Doxorubicin plus ifosfamide can reduce the diameter of target lesions more than doxorubicin alone [21]. Based on these findings, we used the AI regimen as neoadjuvant chemotherapy.

Compared with the ORR associated with AI, that associated with AI + apatinib was significantly improved in patients with STS; similar findings were observed for target lesion shrinkage. Moreover, the rates of R0 and 2-year DFS in the AI + apatinib group were higher than in the comparison group. However, the differences in R0 rate and 2-year DFS were not statistically significant. The error caused by the small sample size may be one reason for the

Table 2 Effectiveness of the treatment

| Characteristics                                | AI + apatinib group (n= 26) | AI group (n= 48) | P-value |
|------------------------------------------------|-----------------------------|-----------------|---------|
| ORR                                            | 53.85% (14/26)              | 29.17% (14/48)  | 0.047   |
| Diameter changes from baseline in target lesion (mm) | -40.46±40.30               | -16.31±34.32    | 0.008   |
| R0 rate                                        | 84.62% (22/26)              | 68.75% (33/48)  | 0.170   |
| DFS rate (2-year)                              | 73.10%                      | 62.50%          | 0.343   |

Data are presented as numbers (percentages) or means± standard deviations

AI neoadjuvant chemotherapy with doxorubicin and ifosfamide, ORR objective response rate, DFS disease-free survival

Table 3 Effectiveness of the treatment in no undifferentiated sarcoma patients

| Characteristics                                | AI + apatinib group (Excluded undifferentiated sarcoma, n= 19) | AI group (Excluded undifferentiated sarcoma, n= 39) | P-value |
|------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------|---------|
| ORR                                            | 52.63% (10/19)                                                   | 28.21% (11/39)                                    | 0.086   |
| Diameter changes from baseline in target lesion (%) | -42.42±38.81                                                   | -14.79±34.36                                     | 0.008   |
| R0 rate                                        | 89.47% (17/19)                                                   | 64.10% (25/39)                                    | 0.061   |
| DFS rate (2-year)                              | 84.20%                                                          | 61.51%                                           | 0.047   |

Data are presented as numbers (percentages) or means± standard deviations

AI neoadjuvant chemotherapy with doxorubicin and ifosfamide, ORR objective response rate, DFS disease-free survival

Fig. 2 Kaplan–Meier estimates of disease-free survival for both treatment groups of all the patients (A) or patients Excluded undifferentiated sarcoma (B)
non-significant between group differences in R0 rate and 2-year DFS observed in this study. In addition, R0 and 2-year DFS were significantly different between the two groups after excluding patients with undifferentiated sarcoma. This suggests that the difference in histological subtypes between the two groups is another reason why the significant ORR in the preoperative evaluation in this study did not convert to a significant R0 and DFS postoperatively. Some patients with other histological subtypes in this study responded well preoperatively but developed recurrence/metastasis shortly after surgery (Fig. 1). This suggests that, for some sarcoma subtypes, higher preoperative ORR does not translate into prolonged postoperative DFS.

Aside from sarcoma subtypes, other factors contribute to preoperative neoadjuvant therapy failure. One such error involves image evaluation. For example, although a patient was recognized as having CR based on imaging findings in evaluating neoadjuvant therapy, postoperative pathology tests confirmed the presence of residual tumor (Fig. 3). There are many other methods to evaluate the perioperative efficacy of neoadjuvant therapy—including imaging, pathological necrosis rate, R0 assessment, etc. However, it is unclear which method most accurately predicts DFS [4, 22, 23]. Well-powered prospective studies are required to answer these questions. In conclusion, although better perioperative outcomes of neoadjuvant therapy do not always translate into better postoperative DFS, better postoperative DFS requires better perioperative outcomes. We can conclude based on these findings that AI + apatinib achieves superior perioperative effectiveness compared to AI alone.

Table 4  Neoadjuvant therapy-related adverse effects per treatment groups

| Characteristics          | AI + apatinib group (n = 26) | AI group (n = 48) | p-value |
|--------------------------|-------------------------------|-------------------|---------|
|                          | All grades | Grade > 2  | All grades | Grade > 2  | All grades | Grade > 2  |         |
| Leukopenia               | 21 (80.77%) | 11 (42.31%) | 36 (75.00%)  | 14 (29.17%) | 0.773     | 0.307     |
| Fatigue                  | 20 (76.92%) | 4 (15.38%)  | 30 (62.50%)  | 3 (6.25%)   | 0.299     | 0.232     |
| Anemia                   | 19 (73.08%) | 8 (30.77%)  | 32 (66.67%)  | 11 (22.92%) | 0.610     | 0.579     |
| Thrombocytopenia         | 19 (73.08%) | 7 (26.92%)  | 33 (68.75%)  | 10 (20.83%) | 0.793     | 0.574     |
| Oral mucositis           | 18 (69.23%) | 5 (19.23%)  | 25 (52.08%)  | 2 (4.17%)   | 0.218     | 0.089     |
| Vomiting                 | 16 (61.54%) | 8 (30.77%)  | 29 (60.42%)  | 3 (6.25%)   | 1.000     | 0.260     |
| Anorexia                 | 18 (69.23%) | 3 (11.54%)  | 23 (47.92%)  | 4 (8.33%)   | 0.092     | 0.691     |
| Transaminase increase    | 12 (46.15%) | 3 (11.54%)  | 17 (35.42%)  | 3 (6.25%)   | 0.456     | 0.659     |

Data are presented as counts (percentages)

AI neoadjuvant chemotherapy with doxorubicin and Ifosfamide

Table 5  Postoperative complications per treatment group

| Complication                        | AI + apatinib group (n = 26) | AI group (n = 48) | p—value |
|-------------------------------------|-------------------------------|-------------------|---------|
| Clavien-Dindo grading               |                               |                   | 0.538   |
| Grade I                             | 1                             | 2                 |         |
| Grade II                            | 4                             | 2                 |         |
| Grade III                           | 2                             | 6                 |         |
| Grade IV                            | 1                             | 1                 |         |
| Grade V                             | 0                             | 0                 |         |
| Wound infection                     | 2 (7.69%)                     | 2 (4.17%)         | 0.609   |
| Pulmonary infection                 | 3 (11.54%)                    | 2 (4.17%)         | 0.337   |
| Hemorrhage                          | 1 (3.85%)                     | 3 (6.25%)         | 1.000   |
| Superficial wound dehiscence        | 1 (3.85%)                     | 2 (4.17%)         | 1.000   |
| Cardiac/respiratory failure         | 1 (3.85%)                     | 0                 | 0.351   |
| Cerebral infarction                 | 0                             | 1 (2.08%)         | 1.000   |
| Deep venous thrombosis              | 0                             | 1 (2.08%)         | 1.000   |
| Readmission                         | 1 (3.85%)                     | 1 (2.08%)         | 1.000   |
| Reoperation                         | 1 (3.85%)                     | 0                 | 0.351   |
| Death                               | 0                             | 0                 | 1.000   |

Data are presented as counts (percentages)

AI neoadjuvant chemotherapy with doxorubicin and Ifosfamide
Neoadjuvant therapy safety is important. Complications associated with neoadjuvant therapy can delay surgery and prolong the overall treatment time. In the present study, the incidence of neoadjuvant treatment-related AEs was similar between groups, as was incidence of postoperative complications. However, we did not rigorously screen patients ahead of enrollment. Patients in a better overall condition were inadvertently more likely to receive combination therapy than their counterparts. This should be considered when reviewing this study’s safety assessment. Nevertheless, the present safety-related findings are consistent with previous studies that used TKIs in combination with chemotherapy for STS [24, 25]. These findings suggest the safety of AI+apatinib as neoadjuvant therapy for STS.

This study had some limitations. This was a retrospective study with small sample size, resulting in low-level evidence. These limitations notwithstanding, our findings suggest that AI+apatinib may be a promising neoadjuvant therapy for STS. It remains unclear whether the perioperative evaluation of neoadjuvant therapy efficacy can support patient prognostication. Different histological subtypes may have different outcomes. Long-term, prospective studies are required to evaluate these considerations.

Conclusions

In conclusion, the apatinib plus doxorubicin and ifosfamide regimen is safe and effective as neoadjuvant therapy for STS. However, the significantly improved preoperative ORR observed after neoadjuvant therapy did not translate into a significantly improved R0 rate and 2-year DFS. Prospective, well-powered studies are warranted to determine the long-term efficacy and optimal application of these protocols.

Authors’ contributions All of the authors have made substantial contributions to the conception. Conception and design: ZT and JW. Patient recruitment and clinical investigation: ZT, JW, JY, FZ, and PL. Analysis and interpretation of data: PZ and XW. ZT and JW conceived the study, participated in its design and coordination, and helped draft the manuscript. All authors have read and approved the manuscript.

Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval The study was approved by the Ethics Committee of the Cancer Hospital affiliated with Zhengzhou University. All procedures performed in studies involving human participants followed the ethical standards of the institutional and/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication All patients provided written informed consent for data collection and research purposes.

Conflicts of interest The authors do not have any potential conflicts of interest to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bourcier K, Le Cesne A, Tselikas L et al (2019) Basic Knowledge in Soft Tissue Sarcoma. Cardiovasc Intervent Radiol 42(9):1255–1261
2. Yang Z, Zheng R, Zhang S et al (2019) Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med 16(3):565–574
3. von Mehren M, Randall RL, Benjamin RS et al (2018) Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(5):536–563
4. Gronchi A, Palмерini E, Quagliuolo V et al (2020) Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol 38(19):2178–2186
5. Tian Z, Zhang F, Li P et al (2020) Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer 20(1):698
6. Tian Z, Yang Y, Yang Y et al (2020) High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer 20(1):1139
7. Byrd DR, Brierley JD, Baker TP et al (2020) Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J Clin
8. Gronchi A, Jones RL (2018) The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk. JAMA Oncol 4(9):1167–1168
9. George S, Wagner AJ (2018) Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. JAMA Oncol 4(9):1169–1170
10. Spalek MJ, Kozak K, Czarnecka AM et al (2020) Neoadjuvant Treatment Options in Soft Tissue Sarcomas. Cancers 12(8)
11. Weiss AR, Chen YL, Scharschmidt TJ et al (2018) Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 21(8):1110–1122
12. Chowdhary M, Sen N, Jeans EB et al (2019) Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol 42(1):1–5
13. Zschaack S, Wust P, Melcher I et al (2018) Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison. Int J Hyperthermia 35(1):1–9
14. Tian Z, Liu H, Zhang F et al (2020) Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma. Invest New Drugs 38(5):1559–1569
15. Yang QK, Chen T, Wang SQ et al (2020) Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis 23(3):279–298
16. Yao W, Wu F, Cai Q et al (2019) Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients. Anticancer Drugs 30(7):e0778
17. Tian Z, Wang W, Liu Z et al (2019) Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions. Cancer Manag Res 11:5293–5300
18. Schuetze SM, Patel S (2009) Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? Oncologist 14(10):1003–1012
19. Tian Z, Niu X, Yao W (2020) Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Front Oncol 10:1642
20. Tian ZC, Wang JQ, Ge H (2020) Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling. J Orthop Translat 22:132–141
21. Judson I, Verweij J, Gelderblom H et al (2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15(4):415–423
22. Gannon NP, Stemm MH, King DM et al (2019) Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma. J Cancer Res Clin Oncol 145(4):1321–1330
23. Salah S, Lewin J, Amir E et al (2018) Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. Cancer Treat Rev 69:1–10
24. Somaiah N, Van Tine BA, Wahlquist AE et al (2020) A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer
25. Wang HY, Chu JF, Zhang P et al (2020) Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma. Onco Targets Ther 13:1561–1568

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.